VEGF and Tyrosine Kinase Inhibitor Nephrotoxicity: Targeted Therapy Review

Written for: Experienced nephrologist audience from onco-nephrology perspective Board-Review Depth: Yes | Practical Management: Yes

OVERVIEW & CLINICAL CONTEXT

Targeted anticancer agents inhibiting VEGF (vascular endothelial growth factor) and its receptors have revolutionized cancer therapy but introduced a new spectrum of nephrotoxicity distinct from traditional cytotoxic chemotherapy. Unlike cisplatin’s proximal tubule toxicity, VEGF pathway inhibitors damage the glomerular endothelium and podocytes, causing proteinuria, hypertension, and thrombotic microangiopathy.

The nephrologist is increasingly asked: - Baseline screening before starting VEGF inhibitor therapy - Management of VEGF-associated hypertension and proteinuria - Recognition and treatment of VEGF-induced thrombotic microangiopathy - When to hold, dose-reduce, or discontinue therapy - Long-term renal outcomes in VEGF inhibitor-treated survivors

VEGF BIOLOGY IN NORMAL KIDNEY PHYSIOLOGY

Essential VEGF Signaling in the Glomerulus

Board Point: VEGF is not just a tumor angiogenesis factor — it is essential for maintaining normal glomerular filtration barrier integrity.

Podocyte-Endothelial Crosstalk

Healthy glomerulus:
├─ Podocytes (visceral epithelium)
│  └─ Produce VEGF-A locally → acts on endothelial VEGFR2
├─ Glomerular endothelial cells (GEC)
│  └─ Express VEGFR1, VEGFR2; receive VEGF signals
└─ Basement membrane + filtration barrier
   └─ Maintained by podocyte-GEC communication via VEGF-VEGFR axis

VEGF Functions in Kidney

Function	Mechanism	Consequence When Blocked
Endothelial cell survival	VEGFR2 signaling; prevents apoptosis	GEC death; capillary collapse
Fenestration maintenance	VEGF maintains endothelial permeability	Loss of filtration surface area
Podocyte integrity	VEGF prevents podocyte apoptosis	Podocyte loss; proteinuria
Glomerular hemodynamics	Maintains vasodilatory tone	Vasoconstriction; reduced GFR
Vascular permeability	Regulated VEGF allows normal filtration	Capillary leak (systemic), or barrier tightening

Key Point: Glomerular endothelium is highly VEGF-dependent — more so than tumor vasculature. VEGF withdrawal causes endothelial injury, not just tumor regression.

ANTI-VEGF MONOCLONAL ANTIBODIES: BEVACIZUMAB

Epidemiology & Incidence of Renal Toxicity

Bevacizumab (Avastin): Recombinant humanized monoclonal antibody targeting VEGF-A; approved for multiple solid tumors (colorectal, breast, lung, renal cell, ovarian, etc.).

Adverse Event	Incidence	Grade 3–4	Onset
Hypertension	25–60%	8–25%	Days to weeks
Proteinuria	21–63%	2–5% (nephrotic-range rare)	Weeks to months
Thrombotic microangiopathy (TMA)	<1% overall	Rare but serious	Variable (days to months)
AKI	2–5%	<1% (usually mild, reversible)	Weeks

Mechanism of Bevacizumab Nephrotoxicity [1]

Endothelial-Podocyte Uncoupling

Antibody binds free VEGF-A → circulating VEGF depleted
Podocyte VEGF signaling → glomerular endothelium blocked
Endothelial cell injury cascade:
- Loss of VEGFR2 survival signals
- Reduced NO production (loss of vasodilatory tone)
- Increased endothelin (vasoconstrictor)
- Endothelial apoptosis, fenestration loss
Podocyte injury from VEGF withdrawal:
- Rhokinase activation (cytoskeletal collapse)
- Loss of slit diaphragm integrity
- Proteinuria develops

Systemic Vascular Effects Contributing to Renal Injury

Hypertension: Widespread endothelial dysfunction + reduced vasodilatory capacity → sustained HTN (mechanism distinct from traditional antihypertensives)
Capillary leak syndrome: Systemic VEGF withdrawal → increased vascular permeability, third spacing, volume depletion
Renal hemodynamic changes: Afferent arteriole vasoconstriction from endothelial dysfunction

Pathology of Bevacizumab-Induced Renal Disease

Thrombotic Microangiopathy (TMA) Pattern [1]

Critical Finding: Large biopsy series shows 98.5% (66/67) of VEGF inhibitor biopsies had renal-limited TMA when kidney injury developed [1].

Pathology: Intracapillary thrombi (fibrin, platelets), MADD (microangiopathic hemolytic anemia) pattern
Electron microscopy: Glomerular capillary swelling, endothelial space enlargement
Immunofluorescence: Negative (rules out immune complex disease)
Clinical features of TMA pattern:
- Thrombocytopenia (may be mild or absent)
- Schistocytes on blood smear (variable)
- Elevated LDH, low haptoglobin
- Mean proteinuria: 2.5 g/day (subnephrotic in most cases)
- Hypertension: 83.5% of TMA cases
- Mean time to onset: 6.9 months post-bevacizumab start

Podocytopathy Pattern (10–15% of Biopsies)

Focal segmental glomerulosclerosis (FSGS) — collapsing or NOS variant
Minimal change disease (MCD)
Mechanism: Direct podocyte injury from VEGF withdrawal

Clinical Management of Bevacizumab-Associated Kidney Disease

Hypertension Management

Board Point: Bevacizumab-HTN is difficult to control because it reflects endothelial dysfunction, not fluid overload or catecholamine excess.

Agent	Efficacy	Notes
ACE-I / ARB	Moderate (50–60% effective)	First-line; may reduce proteinuria; ineffective if monotherapy in severe HTN
CCB (amlodipine, diltiazem)	Good (60–70%)	Works via different mechanism; often needed as second agent
Thiazide diuretics	Limited	Use cautiously (may worsen intravascular volume depletion in TMA)
Beta-blockers	Limited	Not preferred; do not address endothelial dysfunction
Combination therapy	Often needed	ACE-I + CCB + low-dose thiazide typical
Target BP	<130/80	Aggressive control important for kidney protection

Proteinuria Management

RAAS inhibition: ACE-I or ARB standard (even if normotensive) to reduce proteinuria and slow GFR decline
Monitoring: Monthly urine protein; target reduction of 30–50% from baseline
Threshold for intervention: Proteinuria >1 g/day warrants RAAS inhibitor initiation

Indications to Hold or Discontinue Bevacizumab

STOP bevacizumab if: 1. Grade 3–4 hypertension uncontrolled on ≥3 agents 2. Nephrotic-range proteinuria (>3.5 g/day) 3. TMA with microangiopathic hemolytic anemia (schistocytes, elevated LDH, low platelets) 4. Acute severe AKI (Cr rise >50% over days) 5. Posterior reversible encephalopathy syndrome (PRES) (hypertension + neurologic symptoms) 6. Malignant hypertension (BP >180/120 + end-organ signs)

CONSIDER holding if: - eGFR decline >30% compared to baseline - New onset nephrotic syndrome - Grade 2 hypertension refractory to 2 agents after 2 weeks

VEGF RECEPTOR TYROSINE KINASE INHIBITORS (TKIs)

Overview & Classes

VEGF receptor TKIs include multiple mechanisms and agents with varying nephrotoxicity profiles. Unlike monoclonal antibodies, TKIs inhibit multiple intracellular signaling pathways.

Primary VEGF-Targeting TKIs

Agent	Mechanism	Indications	Renal Toxicity Profile
Sunitinib	VEGFR 1/2/3, PDGFR, FLT3	RCC, GIST, NET	High (HTN 40%, proteinuria 20%)
Sorafenib	VEGFR 1/2/3, RAF kinase, FLT3	HCC, RCC	High (HTN 40%, proteinuria 20%)
Pazopanib	VEGFR 1/2/3, PDGFR, c-KIT	RCC, soft tissue sarcoma	High (HTN 40%, proteinuria 20%)
Axitinib	VEGFR 1/2/3 (selective)	RCC	Very high (HTN 60%, proteinuria 30%)
Cabozantinib	VEGFR2, c-MET, RET	RCC, HCC, medullary thyroid	Very high (HTN 60%, proteinuria 25%)
Lenvatinib	VEGFR 1/2/3, FGFR 1–4, RET	Hepatocellular carcinoma	High (HTN 40%, proteinuria 20%)

Mechanisms of TKI-Induced Kidney Injury

Common Pathways (Shared with Bevacizumab)

VEGFR2 inhibition in endothelium → similar glomerular endothelial injury
Podocyte injury → proteinuria, FSGS-like lesions
Systemic endothelial dysfunction → hypertension, capillary leak

TKI-Specific Mechanisms (Not Anti-VEGF Antibodies)

Off-target kinase inhibition:
- PDGFR inhibition (sunitinib, sorafenib) → may cause additional vascular pericyte injury
- FLT3 inhibition → immune activation (some agents)
- Raf kinase inhibition (sorafenib) → independent nephrotoxic effects
Intracellular accumulation: TKIs accumulate in proximal tubule cells; may cause tubular injury in addition to glomerular
Metabolite toxicity: Some TKIs have nephrotoxic active metabolites (e.g., sunitinib)

Pathology of TKI-Induced Kidney Disease

Minimal Change Disease & FSGS Pattern (50–60% of Biopsies)

Finding: Podocyte effacement (similar to post-infectious or drug-induced MCD)
Proteinuria: Often nephrotic range (>3.5 g/day) — distinguishes from bevacizumab
Response to steroids: Variable (50% may respond; suggest partial FSGS component)

TMA Pattern (20–30% of Biopsies)

Similar to bevacizumab-TMA but may be less severe
Less common than podocytopathy pattern (reverse of bevacizumab prevalence)

Acute Tubular Injury

Seen in some TKI biopsies; less common in bevacizumab
Suggests additional mechanism beyond glomerular endothelial injury

Clinical Presentation & Management of TKI Nephrotoxicity

Hypertension

Incidence: 40–60% depending on agent
Severity: Often more severe than bevacizumab-HTN (mechanism: combination of endothelial + PDGFR effects)
Management: Same as bevacizumab; often requires 3–4 agents

Proteinuria

Incidence: 20–30% overall; nephrotic range in 10–15%
Mechanism: Predominantly podocytopathy (vs. TMA with bevacizumab)
Management: RAAS inhibition + monitoring

When to Hold/Dose-Reduce TKI Therapy

Scenario	Action
Grade 1–2 HTN or proteinuria <1 g/day	Continue; optimize BP control
Grade 2 proteinuria (1–2.5 g/day)	Dose reduce 25%; intensify RAAS inhibition
Grade 3 proteinuria (>3.5 g/day)	Hold TKI; reassess after 2–4 weeks of medical management
Grade 3–4 HTN uncontrolled	Dose reduce; hold if uncontrolled after 1 week
TMA with hemolytic anemia	Hold; consider discontinuation; plasma exchange if ADAMTS13 normal
eGFR decline >30% from baseline	Evaluate; may hold or switch to non-VEGF agent

mTOR INHIBITORS: PARTIAL VEGF PATHWAY INVOLVEMENT

Agents & Nephrotoxicity Profile

Agent	Mechanism	Indications	Renal Toxicity
Everolimus	mTOR kinase inhibition (downstream of VEGFR)	mRCC, neuroendocrine tumors, breast cancer	Mild (proteinuria 5–15%, HTN 10–15%)
Temsirolimus	mTOR kinase inhibition + indirect VEGF effects	First-line mRCC	Mild-moderate (proteinuria 5–10%)

Mechanism: mTOR is downstream of VEGFR2 signaling; mTOR inhibition indirectly reduces VEGF production and signaling. Effects milder than direct VEGFR inhibition.

Renal Toxicity Profile: - Proteinuria: Usually mild (<1 g/day); rarely nephrotic - Hypertension: Minimal - AKI: <5% incidence - Hyperglycemia/metabolic: More significant (mTOR effects on glucose metabolism) - Delayed wound healing, canker sores common (non-renal)

BRAF & MEK INHIBITORS

BRAF Inhibitors (Vemurafenib, Dabrafenib)

Renal Toxicity: Uncommon but notable patterns.

Vemurafenib: AIN (acute interstitial nephritis) reported in 1–2% (immune-mediated)
Dabrafenib: Crystal nephropathy reported (active metabolite precipitates in tubules); rare

MEK Inhibitors (Trametinib, Selumetinib, Cobimetinib)

Renal Toxicity: Minimal; not considered nephrotoxic agents.

ALK INHIBITORS & OTHER TARGETED AGENTS

ALK Inhibitors

Agent	Renal Toxicity
Crizotinib	Renal cysts (benign, non-progressive); minimal functional impairment
Alectinib	Minimal
Lorlatinib	Minimal

CDK4/6 Inhibitors (Palbociclib, Ribociclib, Dalpiciclib)

Critical Renal Effect: Serum Creatinine Elevation WITHOUT True GFR Decline

Board Point: This is one of the most commonly misunderstood toxicities in oncology.

Mechanism: - CDK4/6 inhibition blocks proximal tubule creatinine secretion (OCT2-mediated) - Serum creatinine rises 20–40% after starting therapy - True GFR remains unchanged (cystatin C stable; 24-hr urine Cr same) - Reversible upon drug discontinuation

Clinical Implications: - Do NOT discontinue therapy based on Cr rise alone - Calculate eGFR using cystatin C if Cr elevated; compare baseline vs. on-drug cystatin C eGFR - If doubt exists, obtain 24-hour urine creatinine clearance for true GFR assessment - Counsel patients about expected Cr rise (2–3 weeks post-start)

MANAGEMENT PRINCIPLES FOR VEGF/TKI NEPHROTOXICITY

Pre-Treatment Baseline Assessment

Patient planned for VEGF inhibitor therapy
    ↓
Establish baseline:
├─ Serum creatinine, eGFR (KDIGO 2021)
├─ Blood pressure (home readings × 3 days if available)
├─ Urine protein (dipstick + 24-hr urine protein or UPCR)
├─ BMP (K, Na, Mg, PO4, Ca)
├─ CBC (baseline platelets for TMA monitoring)
└─ LDH, haptoglobin (baseline for TMA screening)
    ↓
Optimize baseline:
├─ BP target: <130/80 pre-therapy
├─ Proteinuria: If present, start RAAS inhibitor
└─ eGFR <45: Discuss renal risk; may select alternative agent if non-curative intent

On-Treatment Monitoring Schedule

Timing	Tests	Rationale
Week 2–4	BP, Cr, BMP	Detect early HTN, Cr elevation
Weeks 4–8	Cr, BP, urinalysis + UPCR or 24-hr urine Cr	Assess proteinuria development
Before each cycle	Cr, BMP, BP, urine protein	Cumulative assessment
With proteinuria	CBC, LDH, haptoglobin	Screen for TMA (hemolysis)
Every 3 months	Full metabolic panel, BP log	Trend assessment

Algorithm for Managing Hypertension on VEGF Inhibitors

Patient starting VEGF inhibitor; baseline BP normal
    ↓
Week 2: BP elevated (>140/90)?
    ├─ No → Recheck in 2 weeks
    └─ Yes → Start antihypertensive (see agent table)
    ↓
Week 4: BP controlled (<130/80)?
    ├─ Yes → Continue; monitor monthly
    └─ No → Uptitrate current agent or add second agent
    ↓
Week 8: Still uncontrolled?
    ├─ Yes → Add third agent (combination therapy)
    └─ No → Continue current regimen
    ↓
Week 12: Grade 3–4 HTN despite 3+ agents?
    ├─ Yes → Hold VEGF inhibitor; consider discontinuation or dose reduction
    └─ No → Continue; optimize further if needed
    ↓
Long-term: Monitor BP quarterly; adjust as needed (may improve if VEGF inhibitor held)

Algorithm for Managing Proteinuria on VEGF Inhibitors

Patient on VEGF inhibitor with proteinuria detected
    ↓
Proteinuria level?
    ├─ <0.5 g/day → Observe; recheck in 4 weeks
    ├─ 0.5–1.0 g/day → Start/optimize RAAS inhibitor; recheck in 4 weeks
    ├─ 1.0–3.5 g/day → RAAS inhibitor + consider dose reduction of VEGF inhibitor
    └─ >3.5 g/day (nephrotic) → Hold VEGF inhibitor; evaluate with kidney biopsy if not improving in 2–4 weeks
    ↓
Repeat urine protein in 4 weeks after intervention
    ├─ Improved >30% → Continue therapy; monitor closely
    ├─ Stable → Reassess; may need further dose reduction or switch agent
    └─ Worsening → Hold; consider discontinuation if not curative intent
    ↓
With RAAS inhibitor + proteinuria still nephrotic:
    ├─ Kidney biopsy indicated → guides prognosis & further therapy
    └─ Biopsy shows FSGS/MCD → Discuss with oncology: hold vs. continue depending on cancer prognosis
    ↓
If TMA features present (schistocytes, low plts, high LDH):
    └─ Hold VEGF inhibitor urgently; plasma exchange if severe; oncology consult for alternative therapy

SYNERGISTIC NEPHROTOXICITY: VEGF INHIBITORS + PLATINUM AGENTS

Critical Board Point: Combination therapy (e.g., bevacizumab + cisplatin in many regimens) carries synergistic nephrotoxicity risk.

Mechanisms of Synergy

Cisplatin → proximal tubule injury, AKI, electrolyte wasting
VEGF inhibitor → glomerular injury, proteinuria, HTN
Together → combined renal functional decline, higher risk for dialysis-dependent AKI

Practical Management

Baseline eGFR essential before combination therapy
Aggressive hydration (for cisplatin) + intensive BP management (for VEGF inhibitor)
More frequent monitoring: Bi-weekly Cr, BMP, urinalysis
Earlier intervention: If Cr rises >25% (vs. >30%) or proteinuria develops, consider holding or dose reduction sooner
Long-term follow-up: Expect higher rates of chronic CKD in survivors

LONG-TERM RENAL OUTCOMES

Post-VEGF Inhibitor Renal Function

Key Statistic: Most VEGF inhibitor-induced renal dysfunction is reversible upon drug discontinuation; however, some patients have lasting injury.

Short-term recovery: HTN, proteinuria, mild AKI usually improve within 4–12 weeks post-discontinuation
Persistent CKD: 10–15% of patients with severe proteinuria or TMA have lasting eGFR decline
Risk factors for chronic sequelae:
- Severity of proteinuria at diagnosis (nephrotic range worse)
- Duration of VEGF inhibitor exposure (>12 months higher risk)
- Cumulative renal injury (prior nephrotoxic agents)
- Age >65 years
- Baseline CKD

Post-TMA Prognosis

VEGF-induced TMA: 70–80% recover normal renal function within 6–12 months post-discontinuation (unlike HUS/TTP)
Plasma exchange: Role unclear; if ADAMTS13 normal and diagnosis is VEGF-TMA (not TTP), PE may not help; supportive care typically sufficient
Some patients: Residual proteinuria or modest eGFR decline persist

📚 CITED REFERENCES (PubMed-verified)

References rebuilt 2026-05-03 with PubMed-verified PMIDs. Phase 2 audit (mastery-non-htn-Reference_Check.md) flagged the prior version's PMC-only citations as a structural defect — many references lacked PMIDs and some had wrong journal/year metadata. Below: verified entries (PubMed-confirmed) and partial entries (citation text retained but PMID could not be matched). [Bibliography rebuilt 2026-05-03]

[1] Rashidi A, Wanchoo R, Izzedine H. How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor. Clin J Am Soc Nephrol. 2023;18(1):121-123. PMID: 35977777. — Comprehensive management approach from onco-nephrology perspective. [Corrected 2026-05-03 — prior version cited journal as "Clinical Kidney Journal"; actual journal is CJASN per PubMed metadata.]

[2] Hanna RM, Lopez EA, Hasnain H, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2019;12(1):92-100. PMID: 30746134. — Case series highlighting systemic renal effects of intravitreal VEGF inhibition.

[3] Estrada CC, Maldonado A, Mallipattu SK. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187-200. PMID: 30642877. — Comprehensive review of VEGFA-VEGFR2 inhibition mechanisms and TMA / glomerulopathy patterns. [Corrected 2026-05-03 — prior version cited year 2018; actual epub Jan 14, 2019.]

[4] Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-1136. PMID: 18337603. — Landmark TMA case series establishing VEGF-inhibitor-associated renal TMA as a distinct clinical entity. [Note — this is the canonical 2008 NEJM paper; the prior version's "Historical reference (2006)" date attribution was incorrect per PubMed metadata.]

[5] Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors. Hypertens Res. 2019;42(11):1799-1801 (related; for the Kidney Int 2019 reference cited in lecture please verify PMID against the specific Kidney Int paper). [Bibliography note — the lecture's "Nephrotoxicity Induced by Intravitreal VEGF Inhibitors — Kidney International, 2019" citation could not be uniquely matched to a specific Kidney Int paper in 2019 from my Phase 2 search. Multiple Hanna et al. and Wanchoo et al. papers exist on this topic in 2018-2020 across CKJ, Hypertens Res, and adjacent journals; recommend Andy verifies the intended source PMID and updates this reference.]

[6] References 4 (Effects of VEGF Inhibitor-Induced Proteinuria), 5 (Ocular and Systemic VEGF Ligand Inhibitor Use), 6 (Bevacizumab-Induced Renal-Limited TMA), 7 (Review of Intravitreal VEGF Inhibitor Toxicity) from the prior version — citation text retained for human reconciliation; PMIDs not confirmed against PubMed in this Phase 2 pass. [Bibliography note 2026-05-03 — when Andy updates these to specific papers, please add verified PMIDs. The qualitative content these citations support (TMA pattern, intravitreal systemic exposure, transplant-specific patterns) is established in the verified references above.]

Last Updated: 2026-02-28 Review Cycle: Annually or upon new agent FDA approval Author Perspective: Onco-nephrology clinical practice, board review emphasis